Torrent Pharmaceuticals revenue and financials
₹4,710.00Change from previous close: −1.42%Absolute change: −₹68.00
In the fiscal year ended March 2026, Torrent Pharmaceuticals reported revenue of ₹139.8B (+21.39% year over year). Net income was ₹21.63B, a net margin of 15.5%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +21.39%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +13.19%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 15.5%
- FY to Mar 2025: 16.6%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 49,210 | 41,967 | 33,030 | 33,020 | 31,780 | 29,591 | 28,090 | 28,890 | 28,590 | 27,448 | 27,320 | 26,600 |
| Cost of revenue | 11,630 | 10,152 | 7,990 | 8,000 | 7,740 | 7,309 | 6,730 | 6,780 | 6,940 | 6,792 | 6,970 | 6,600 |
| Gross profit | 37,580 | 31,816 | 25,040 | 25,020 | 24,040 | 22,282 | 21,360 | 22,110 | 21,650 | 20,656 | 20,350 | 20,000 |
| Selling, general and administrative | 8,930 | 8,483 | 6,510 | 6,270 | 6,050 | 6,288 | 5,490 | 5,430 | 5,500 | 5,186 | 4,960 | 5,030 |
| Operating income | 10,710 | 8,478 | 8,820 | 8,790 | 8,310 | 7,631 | 7,150 | 7,410 | 7,270 | 6,924 | 6,560 | 6,240 |
| EBIT | 10,710 | 8,478 | 8,820 | 8,790 | 8,310 | 7,631 | 7,150 | 7,410 | 7,270 | 6,924 | 6,560 | 6,240 |
| EBITDA | 13,353 | 11,120 | 10,694 | 10,815 | 10,184 | 9,505 | 9,031 | 9,385 | 9,151 | 8,805 | 8,217 | 8,200 |
| Interest expense | 3,050 | 2,357 | 450 | 480 | 560 | 554 | 570 | 640 | 750 | 786 | 800 | 910 |
| Pre-tax income | 7,330 | 5,292 | 8,140 | 7,910 | 7,380 | 6,648 | 6,910 | 6,610 | 6,560 | 6,311 | 6,310 | 5,590 |
| Income tax | 1,670 | 1,650 | 1,790 | 2,000 | 1,900 | 1,666 | 1,880 | 2,080 | 1,990 | 1,817 | 1,880 | 1,730 |
| Net income | 5,660 | 3,894 | 6,350 | 5,910 | 5,480 | 4,983 | 5,030 | 4,530 | 4,570 | 4,494 | 4,430 | 3,860 |
| Net income to common shareholders | 5,660 | 3,894 | 6,350 | 5,910 | 5,480 | 4,983 | 5,030 | 4,530 | 4,570 | 4,494 | 4,430 | 3,860 |
| Basic EPS | 14.87 | 11.52 | 18.77 | 17.45 | 16.19 | 14.72 | 14.88 | 13.37 | 13.51 | 13.28 | 13.10 | 11.39 |
| Diluted EPS | 14.87 | 11.52 | 18.77 | 17.45 | 16.19 | 14.72 | 14.88 | 13.37 | 13.51 | 13.28 | 13.10 | 11.39 |
| Average shares (basic) | 381 | 338 | 338 | 339 | 338 | 339 | 338 | 339 | 338 | 338 | 338 | 339 |
| Average shares (diluted) | 381 | 338 | 338 | 339 | 338 | 339 | 338 | 339 | 338 | 338 | 338 | 339 |
| Dividend per share | — | 9.00 | 29.00 | — | — | 6.00 | 26.00 | — | — | 6.00 | 22.00 | — |